138
|
462
|
6rbiA |
Crystal structure of kdm5b in complex with 5-(1h-tetrazol-5-yl)quinolin-8-ol |
92
|
318
|
6dq4A |
Linked kdm5a jmj domain bound to the inhibitor gsk-j1 |
94
|
317
|
6dq6A |
Linked kdm5a jmj domain bound to the inhibitor n44 i.e. 3-((2-(pyridin-2-yl)-6-(4-(vinylsulfonyl)-1,4-diazepan-1-yl)pyrimidin-4-yl)amino)propanoic acid |
87
|
318
|
6dq8A |
Linked kdm5a jmj domain bound to the inhibitor n49 i.e. 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid |
88
|
316
|
6dq5A |
Linked kdm5a jmj domain bound to the inhibitor n43 i.e. 3-((6-(4-acryloyl-1,4-diazepan-1-yl)-2-(pyridin-2-yl)pyrimidin-4-yl)amino)propanoic acid |
86
|
318
|
6dqbA |
Linked kdm5a jmj domain forming covalent bond to inhibitor n71 i.e. 2-((3-(4-(dimethylamino)but-2-enamido)phenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid |
87
|
318
|
6dqaA |
Linked kdm5a jmj domain bound to inhibitor n70 i.e.[2-((3-aminophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid] |
87
|
318
|
6dq9A |
Linked kdm5a jmj domain bound to the covalent inhibitor n69 i.e. [2-((3-acrylamidophenyl)(2-(piperidin-1-yl)ethoxy)methyl)thieno[3,2-b]pyridine-7-carboxylic acid] |
101
|
331
|
6etgA |
Crystal structure of kdm4d with tetrazolhydrazide compound 6 |
98
|
330
|
6etsA |
Crystal structure of kdm4d with tetrazolhydrazide compound 1 |
103
|
330
|
6etuA |
Crystal structure of kdm4d with tetrazolhydrazide compound 7 |
105
|
327
|
6f5rA |
Crystal structure of kdm4d with gf028 ligand |
104
|
330
|
6f5sA |
Crystal structure of kdm4d with tetrazole ligand gf049 |
97
|
329
|
6ettA |
Crystal structure of kdm4d with tetrazole compound 4 |
107
|
330
|
6f5qA |
Crystal structure of kdm4d with gf026 ligand |
102
|
330
|
6f5tA |
Crystal structure of kdm4d with tetrazole ligand gf057 |
104
|
330
|
6etvA |
Crystal structure of kdm4d with tetrazolhydrazide compound 2 |
104
|
330
|
6eteA |
Crystal structure of kdm4d with tetrazolhydrazide compound 5 |
99
|
330
|
6etwA |
Crystal structure of kdm4d with tetrazolhydrazide compound 3 |
144
|
472
|
6ip0A |
Crystal structure of arabidopsis thaliana jmj13 catalytic domain in complex with akg |
114
|
351
|
6g5xA |
Crystal structure of kdm4a with compound yp-02-145 |
138
|
471
|
6ip4A |
Crystal structure of arabidopsis thaliana jmj13 catalytic domain in complex with nog and an h3k27me3 peptide |
114
|
349
|
6g5wA |
Crystal structure of kdm4a with compound yp-03-038 |
88
|
317
|
5islA |
Linked kdm5a jmj domain bound to the inhibitor c49 (2-{[(2-{[(e)-2-(dimethylamino)ethenyl](ethyl)amino}-2-oxoethyl)amino]methyl}pyridine-4-carboxylic acid) |
142
|
461
|
5lwbA |
Crystal structure of human jarid1b in complex with s40650a |
104
|
349
|
5ly1A |
Jmjd2a/ kdm4a complexed with ni(ii) and macrocyclic peptide inhibitor cp2 (13-mer) |
150
|
462
|
5lw9A |
Crystal structure of human jarid1b in complex with s40563a |
110
|
340
|
5kr7A |
Kdm4c bound to pyrazolo-pyrimidine scaffold |
88
|
317
|
5ivvA |
Linked kdm5a jmj domain bound to the inhibitor n12 [3-((1-methyl-1h-pyrrolo[2,3-b]pyridin-3-yl)amino)isonicotinic acid] |
93
|
318
|
5iveA |
Linked kdm5a jmj domain bound to the inhibitor n8 ( 5-methyl-7-oxo-6-(propan-2-yl)-4,7-dihydropyrazolo[1,5-a]pyrimidine-3-carbonitrile) |
91
|
317
|
5ivjA |
Linked kdm5a jmj domain bound to the inhibitor n11 [3-({1-[2-(4,4-difluoropiperidin-1-yl)ethyl]-5-fluoro-1h-indazol-3-yl}amino)pyridine-4-carboxylic acid] |
94
|
317
|
5ivcA |
Linked kdm5a jmj domain bound to the inhibitor n3 (4'-[(2-phenylethyl)carbamoyl][2,2'-bipyridine]-4-carboxylic acid) |
90
|
317
|
5ivbA |
A high resolution structure of a linked kdm5a jmj domain with alpha-ketoglutarate |
91
|
317
|
5ivfA |
Linked kdm5a jmj domain bound to the inhibitor n10 8-(1-methyl-1h-imidazol-4-yl)-2-(4,4,4-trifluorobutoxy)pyrido[3,4-d]pyrimidin-4-ol |
145
|
462
|
5fpuA |
Crystal structure of human jarid1b in complex with gskj1 |
107
|
345
|
5f3cA |
Crystal structure of human kdm4a in complex with compound 52d |
101
|
346
|
6h8pA |
Jmjd2a/ kdm4a complexed with ni(ii), nog and histone h1.4(18-32)k26me3 peptide (15-mer) |
141
|
462
|
6eiuA |
Crystal structure of kdm5b in complex with kdopz29a |
142
|
459
|
6ej1A |
Crystal structure of kdm5b in complex with kdopz48a. |
140
|
458
|
6ej0A |
Crystal structure of kdm5b in complex with kdopz000049a. |
142
|
462
|
6einA |
Crystal structure of kdm5b in complex with s49365a. |
145
|
461
|
6eiyA |
Crystal structure of kdm5b in complex with kdopz000034a. |
101
|
350
|
6cg1A |
Crystal structure of kdm4a with compound 14 |
104
|
348
|
6cg2A |
Crystal structure of kdm4a with compound 8 |
85
|
318
|
6bh3A |
Linked kdm5a jmj domain bound to the inhibitor (s)-n-(1-(3-isopropyl-1h-pyrazole-5-carbonyl)pyrrolidin-3-yl)cyclopropanecarboxamide (compound n55) |
93
|
318
|
6bgyA |
Linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2-(1-methylpyrrolidin-2-yl)ethoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7-carboxylic acid(compound 46) |
89
|
318
|
6bguA |
Linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(propoxy)methyl)-1h-pyrrolo[3,2-b]pyridine (compound n9) |
86
|
318
|
6bgzA |
Linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2-(1-methyl-1h-imidazol-2-yl)ethoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7-carboxylic acid (compound n47) |
88
|
317
|
6bh5A |
Linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(3-(piperidin-1-yl)propoxy)methyl)-1h-pyrrolo[3,2-b]pyridine-7-carboxylic acid (compound n48) |
88
|
318
|
6bgvA |
Linked kdm5a jmj domain bound to the inhibitor 2-((2-chlorophenyl)(2-(piperidin-1-yl)ethoxy)methyl)-1l2-pyrrolo[3,2-b]pyridine-7-carboxylic acid (compound n40) |